
Eric M Sanford

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/6813408/publications.pdf Version: 2024-02-01



FRIC M SANFORD

#	Article	IF	CITATIONS
1	Development and validation of a clinical cancer genomic profiling test based on massively parallel DNA sequencing. Nature Biotechnology, 2013, 31, 1023-1031.	17.5	1,785
2	Activation of MET via Diverse Exon 14 Splicing Alterations Occurs in Multiple Tumor Types and Confers Clinical Sensitivity to MET Inhibitors. Cancer Discovery, 2015, 5, 850-859.	9.4	632
3	A computational approach to distinguish somatic vs. germline origin of genomic alterations from deep sequencing of cancer specimens without a matched normal. PLoS Computational Biology, 2018, 14, e1005965.	3.2	191
4	Genomic Alterations Observed in Colitis-Associated Cancers Are Distinct From Those Found in Sporadic Colorectal Cancers and Vary by Type of Inflammatory Bowel Disease. Gastroenterology, 2016, 151, 278-287.e6.	1.3	147
5	A Novel Next-Generation Sequencing Approach to Detecting Microsatellite Instability and Pan-Tumor Characterization of 1000 Microsatellite Instability–High Cases in 67,000 Patient Samples. Journal of Molecular Diagnostics, 2019, 21, 1053-1066.	2.8	147
6	Comprehensive Genomic Profiling Identifies a Subset of Crizotinib-Responsive <i>ALK</i> -Rearranged Non-Small Cell Lung Cancer Not Detected by Fluorescence In Situ Hybridization. Oncologist, 2016, 21, 762-770.	3.7	119
7	Enrichment of Targetable Mutations in the Relapsed Neuroblastoma Genome. PLoS Genetics, 2016, 12, e1006501.	3.5	98
8	Identification and characterization of <i>RET</i> fusions in advanced colorectal cancer. Oncotarget, 2015, 6, 28929-28937.	1.8	94
9	Comprehensive Genomic Profiling of Advanced Penile Carcinoma Suggests a High Frequency of Clinically Relevant Genomic Alterations. Oncologist, 2016, 21, 33-39.	3.7	69
10	Prospective Comprehensive Genomic Profiling of Advanced Gastric Carcinoma Cases Reveals Frequent Clinically Relevant Genomic Alterations and New Routes for Targeted Therapies. Oncologist, 2015, 20, 499-507.	3.7	64
11	HER2-Overexpressing Breast Cancers Amplify FGFR Signaling upon Acquisition of Resistance to Dual Therapeutic Blockade of HER2. Clinical Cancer Research, 2017, 23, 4323-4334.	7.0	64
12	Gene Networks with Transcriptional Bursting Recapitulate Rare Transient Coordinated High Expression States in Cancer. Cell Systems, 2020, 10, 363-378.e12.	6.2	54
13	Antitumor Response of VEGFR2- and VEGFR3-Amplified Angiosarcoma to Pazopanib. Journal of the National Comprehensive Cancer Network: JNCCN, 2016, 14, 499-502.	4.9	32
14	Gene regulation gravitates toward either addition or multiplication when combining the effects of two signals. ELife, 2020, 9, .	6.0	13
15	Evaluation of microsatellite instability (MSI) status in 11,573 diverse solid tumors using comprehensive genomic profiling (CGP) Journal of Clinical Oncology, 2016, 34, 1523-1523.	1.6	10
16	Evaluation of microsatellite instability (MSI) status in gastrointestinal (GI) tumor samples tested with comprehensive genomic profiling (CGP) Journal of Clinical Oncology, 2016, 34, 528-528.	1.6	6
17	Germline variants in cancer risk genes detected by NGS-based comprehensive tumor genomic profiling (CGP) Journal of Clinical Oncology, 2015, 33, 11084-11084.	1.6	5
18	Patient Derived Xenograft (PDX) Models Recapitulate the Genomic-Driver Composition of Acute Leukemia Samples. Blood, 2014, 124, 286-286.	1.4	4

ERIC M SANFORD

#	Article	IF	CITATIONS
19	Patient Derived Xenograft (PDX) Models Faithfully Recapitulate The Genetic Composition Of Primary AML. Blood, 2013, 122, 1328-1328.	1.4	2
20	Identification Of Actionable Genomic Alterations In Hematologic Malignancies By a Clinical Next Generation Sequencing-Based Assay. Blood, 2013, 122, 230-230.	1.4	2
21	Pilot Study To Evaluate The Prevalence Of Actionable Oncogenic Mutations In Patients With Relapsed Refractory Multiple Myeloma. Blood, 2013, 122, 755-755.	1.4	1
22	Comprehensive Mutational Profiling In Myelodysplastic Syndromes Treated With Decitabine and Tretinoin. Blood, 2013, 122, 2791-2791.	1.4	0
23	Comprehensive genomic profiling of anal squamous cell carcinoma to reveal frequency of clinically relevant genomic alterations in the PI3K/mTOR pathway Journal of Clinical Oncology, 2015, 33, 3522-3522.	1.6	0
24	Genomic analysis of colitis-associated cancers Journal of Clinical Oncology, 2015, 33, 3566-3566.	1.6	0
25	Comprehensive genomic profiling identifies clinically relevant genomic alterations in relapsed and metastatic penile squamous cell carcinoma Journal of Clinical Oncology, 2015, 33, e15628-e15628.	1.6	Ο